Evidence map›Paper›PMID 34110924›Full record

ArticleBioanalysis2021

Analytical considerations for reducing the matrix effect for the sphingolipidome quantification in whole blood.

Dezhen Wang, Peining Xu, Clementina Mesaros

Abstract read
In one paragraph

Article in Bioanalysis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dezhen WangDepartment of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Peining XuDepartment of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Clementina MesarosDepartment of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID https://orcid.org/0000-0001-5117-2038

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Trevor M Penning · 2006 to 2026
$35.3M
Lipid metabolism disruption as a consequence of mitochondrial dysfunction in Friedreich's ataxiaR21NS116315 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI MESAROS, A. CLEMENTINA · 2020 to 2020
$486k
National Institutes of Health, US P30ES013508, R21NS116315NIEHS NIH HHS P30 ES013508NINDS NIH HHS R21 NS116315
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAlkaliesButanolsChromatography, LiquidFemaleHumansHydrolysisLipidomicsMaleMass SpectrometryMethyl EthersPlasmaSphingolipidsAlkaliesButanolsMethyl Ethersmethyl tert-butyl etherSphingolipidsceramideshigh-resolution mass spectrometryplasmasphingolipidswhole blood

Identifiers

PMID34110924
PMCPMC8240607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.